Becton Dickinson and Co
NYSE:BDX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Becton Dickinson and Co
NYSE:BDX
|
US |
|
D
|
Danaher Corp
F:DAP
|
US |
|
M
|
Metair Investments Ltd
F:M4HA
|
ZA |
|
International Paper Co
NYSE:IP
|
US |
Intrinsic Value
Is BDX undervalued or overvalued?
See the intrinsic value estimate for Becton Dickinson and Co and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
BDX looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with BDX’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Becton Dickinson and Does
Becton Dickinson, better known as BD, makes medical devices and supplies used in hospitals, labs, doctor offices, and by patients at home. Its core products include needles, syringes, catheters, blood collection systems, infusion and medication-delivery equipment, and diagnostic tools that help identify infections and other conditions. The company sits deep in the healthcare supply chain, where its products are used every day and are often needed in large, steady volumes.
- Headquarters
- United States of America US
- Employees
- 72 000
- IPO date
- Sep 25, 1963
Becton Dickinson and has a narrow economic moat
Replacing BD’s medication systems means changing hospital software connections, retraining staff and checking that care can continue safely, making a cheaper rival less attractive. Patents on selected medical-device designs also prevent competitors from copying protected features directly, although these protections do not cover every product BD sells.
Read the full moat analysis
Revenue & Expenses Breakdown
Becton Dickinson and Co
Earnings Waterfall
Becton Dickinson and Co
The intrinsic value for Becton Dickinson and Co (BDX) under the Base Case is hidden USD.
Compared with the current market price of 198.41 USD, the stock appears hidden.